News

Glenmark Pharma board to consider interim dividend on September 26The record date for payment of the interim dividend has been fixed as Tuesday, September 30. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,014.35, down by ₹70.25 or 3.37%, on the BSE today, September 22.By Jomy Jos Pullokaran   September 22, 2025, 5:16:04 PM IST (Published)2 Min ReadDrug firm Glenmark Pharmaceuticals Ltd on Monday (September 22) informed that a meeting of its board of directors will be held on Friday, September 26, 2025, to consider and approve payment of interim dividend, if any, on equity shares of the company for FY26.

The company further stated that the record date for payment of the interim dividend, if declared, has been fixed as Tuesday, September 30, 2025.

First quarter results

Glenmark Pharmaceuticals reported an 86.2% year-on-year (YoY) decline in net profit at ₹46.8 crore for the first quarter that ended June 30, 2025, down from ₹340.2 crore in Q1FY25. However, revenue increased slightly, up 0.6% at ₹3,264 crore against ₹3,244 crore in the same quarter last year.

Also Read: Glenmark Pharma announces India launch of blood cancer treatment Brukinsa

At the operating level, EBITDA dipped 1.4% to ₹580 crore in this quarter compared to ₹588.2 crore YoY. The EBITDA margin was lower at 17.7% versus 18.1% in the April-July quarter of the previous fiscal.

In India, sales from Glenmark Pharmaceuticals’ formulation business in the first quarter of FY26 stood at ₹1,239.9 crore, compared with ₹1,196.2 crore a year ago, reflecting a 3.7% YoY growth.

In North America, the business registered revenue of ₹778 crore for this quarter, compared with ₹714.6 crore in the fourth quarter of FY25, marking an 8.9% quarter-on-quarter (QoQ) increase. The growth was driven by share gains in injectable product launches and partnered products.

Also Read: Glenmark Pharma's innovation arm signs exclusive licensing agreement with AbbVie for ISB 2001

Revenue from emerging markets, including RCIS, LATAM, MEA, and APAC, was ₹572.1 crore in the first quarter of FY26, compared with ₹570.8 crore in the year-ago period, registering a 0.2% YoY rise. The company continues to anticipate double-digit growth on a constant currency basis.

Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,014.35, down by ₹70.25 or 3.37%, on the BSE today, September 22.

Continue Reading(Edited by : Shoma Bhattacharjee)Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsGlenmark Pharmaceuticalsshare market today